Andrew J Armstrong
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly W, Danila D, Lin C, Lee J, Matsubara N, Ward P, Armstrong A, Pook D, Kim M, Dorff T, Fischer S, Lin Y, Horvath L, Sumey C, Yang Z, Jurida G, Smith K, Connarn J, Penny H, Stieglmaier J, Appleman L. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov 2023:OF1-OF14.
Oct 20, 2023Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Oct 20, 2023Cancer Discov 2023:OF1-OF14
Kelly William K, Danila D C, Lin Chia-Chi, Lee Jae-Lyun, Matsubara Nobuaki, Ward Patrick J, Armstrong Andrew J, Pook David, Kim Miso, Dorff Tanya, Fischer Stefanie, Lin Yung-Chang, Horvath L G, Sumey Christopher, Yang Zhao, Jurida Gabor, Smith Kristen M, Connarn Jamie N, Penny Hweixian L, Stieglmaier Julia, Appleman Leonard J
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
Sonpavde G, Pond G, Templeton A, Fandi A, Tombal B, Rosenthal M, Armstrong A, Petrylak D. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. Eur Urol 2015
Oct 20, 2015Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
Oct 20, 2015Eur Urol 2015
Sonpavde Guru, Pond Gregory R, Templeton Arnoud, Fandi Abderrahim, Tombal Bertrand, Rosenthal Mark, Armstrong Andrew J, Petrylak Daniel P
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer
Sonpavde G, Smith M, Lechuga M, Chow-Maneval E, Chen I, Paolini J, Wang S, Templeton A, Vardy J, Clarke S, Armstrong A, Pond G, Michaelson M. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2014; 12:317-24.
Mar 15, 2014Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer
Mar 15, 2014Clin Genitourin Cancer 2014; 12:317-24
Sonpavde Guru, Smith Matthew R, Lechuga Mariajose, Chow-Maneval Edna, Chen Isan, Paolini Jolanda, Wang Shaw-Ling, Templeton Arnoud, Vardy Janette L, Clarke Stephen J, Armstrong Andrew J, Pond Gregory R, Michaelson M Dror